Hong Sun1,2, Qiang Qu1,3, Jian Qu1, Xiao-Ya Lou1, Yan Peng1, Ying Zeng1, Guo Wang1. 1. Department of Clinical Pharmacology, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University Xiangya School of Medicine, Changsha 410078, PR China. 2. Department of Pharmacy, Provincial Clinical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou 350001, PR China. 3. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, PR China.
Abstract
AIMS: To explore the effect of urate transporter 1 (URAT1) polymorphisms on the hypertensive patients with hyperuricemia and the uricosuric action of losartan therapy among hypertensive patients with hyperuricemia. METHODS: 101 hypertensive patients with hyperuricemia were detected the genotypes of URAT1 rs1529909 and rs3825016 and undergo a 2-weeks following losartan treatment. Before and after treatment, serum uric acid (SUA) and other clinical data were compared between different genotypes of URAT1 patients. RESULTS: The frequency of rs3825016 (C/T) CT genotype was significant higher in the hypertensive patients with hyperuricemia than that in the healthy controls (32.7 vs 18.8%; p = 0.02). After lorsatan treatment, the patients with the rs3825016 (C/T) or rs1529909 (T/C) mutant genotypes had lower decreased value (DV) of SUA compared with the patients who are wild-type of the variant (p = 0.001 and p < 0.001, respectively). Combined the two variants together, the DV of SUA in two variants both wild-type patients higher than that in the two variants mutant patients (p < 0.0001). CONCLUSION: These results suggest that URAT1 rs3825016 and rs1529909 polymorphisms influence the uricosuric action of losartan. Original submitted 20 August 2014; Revision submitted 15 April 2015.
AIMS: To explore the effect of urate transporter 1 (URAT1) polymorphisms on the hypertensivepatients with hyperuricemia and the uricosuric action of losartan therapy among hypertensivepatients with hyperuricemia. METHODS: 101 hypertensivepatients with hyperuricemia were detected the genotypes of URAT1rs1529909 and rs3825016 and undergo a 2-weeks following losartan treatment. Before and after treatment, serum uric acid (SUA) and other clinical data were compared between different genotypes of URAT1patients. RESULTS: The frequency of rs3825016 (C/T) CT genotype was significant higher in the hypertensivepatients with hyperuricemia than that in the healthy controls (32.7 vs 18.8%; p = 0.02). After lorsatan treatment, the patients with the rs3825016 (C/T) or rs1529909 (T/C) mutant genotypes had lower decreased value (DV) of SUA compared with the patients who are wild-type of the variant (p = 0.001 and p < 0.001, respectively). Combined the two variants together, the DV of SUA in two variants both wild-type patients higher than that in the two variants mutant patients (p < 0.0001). CONCLUSION: These results suggest that URAT1rs3825016 and rs1529909 polymorphisms influence the uricosuric action of losartan. Original submitted 20 August 2014; Revision submitted 15 April 2015.